The novel antiviral letermovir is as good as the current standard of care valganciclovir in preventing cytomegalovirus (CMV) infection in post-kidney transplant patients, but with less toxicity, according to a phase III trial presented at IDWeek 2022.
Early antiretroviral therapy (ART) in individuals with HIV offers better outcomes, particularly in those aged 35 years and younger, in a follow-up analysis of the START trial. Conversely, delayed therapy results in a higher risk of death and serious health issues in this population.
Patients who are refractory or intolerant to currently approved antifungal therapies exhibited a positive response to the novel triterpenoid antifungal ibrexafungerp, according to interim analysis results of the phase III FURI trial.
The use of an exhalation delivery system with fluticasone (EDS-FLU) significantly reduces acute exacerbations of chronic rhinosinusitis (CRS), which may help drive down the need for antibiotics and prevent antibiotic resistance, in the ReOpen1 and 2 randomized controlled trials.
Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.
While rare, infection with antibiotic-resistant gram-negative bacteria (AR-GNB) following a positive COVID-19 diagnosis is more severe and often results in worse outcomes, according to a study presented at the recent Virtual ID Week 2022.
A digital microfluidic (DMF) device can reduce time to detect bacteria by as much as 9 hours, speeding up the diagnosis of neonatal sepsis, as shown in a study presented at IDWeek 2022 in Washington, DC, US.
Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.
In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).
Treatment with the nucleos(t)ide analogue (NUC) tenofovir alafenamide (TAF) for 2 years leads to improvements in liver stiffness among patients with chronic hepatitis B (CHB), including those with advanced liver fibrosis, according to a study presented at the IDWeek 2022 in Washington, DC, US.